MEI Pharma http://investor.meipharma.com/ Helsinn Group and MEI Pharma Announce First Patient Dosed in Phase 2 Dose-Optimization Study of Pracinostat and Azacitidine in Myelodysplastic Syndrome http://investor.meipharma.com/2017-06-14-Helsinn-Group-and-MEI-Pharma-Announce-First-Patient-Dosed-in-Phase-2-Dose-Optimization-Study-of-Pracinostat-and-Azacitidine-in-Myelodysplastic-Syndrome Two-stage study designed to evaluate tolerability and efficacy of pracinostat combined with azacitidine in patients with high and very high risk MDS Wed, 14 Jun 2017 05:30:00 -0700 http://investor.meipharma.com/2017-06-14-Helsinn-Group-and-MEI-Pharma-Announce-First-Patient-Dosed-in-Phase-2-Dose-Optimization-Study-of-Pracinostat-and-Azacitidine-in-Myelodysplastic-Syndrome Helsinn Group and MEI Pharma Report Correlation between Mutations in DNA Methylation Pathway and Clinical Response in Phase II Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia http://investor.meipharma.com/2017-06-05-Helsinn-Group-and-MEI-Pharma-Report-Correlation-between-Mutations-in-DNA-Methylation-Pathway-and-Clinical-Response-in-Phase-II-Study-of-Pracinostat-and-Azacitidine-in-Acute-Myeloid-Leukemia Mon, 05 Jun 2017 06:00:00 -0700 http://investor.meipharma.com/2017-06-05-Helsinn-Group-and-MEI-Pharma-Report-Correlation-between-Mutations-in-DNA-Methylation-Pathway-and-Clinical-Response-in-Phase-II-Study-of-Pracinostat-and-Azacitidine-in-Acute-Myeloid-Leukemia MEI Pharma Announces Pre-Specified Response Rate Exceeded in Dose-Escalation Study of ME-401 in Chronic Lymphocytic Leukemia and Follicular Lymphoma http://investor.meipharma.com/2017-05-31-MEI-Pharma-Announces-Pre-Specified-Response-Rate-Exceeded-in-Dose-Escalation-Study-of-ME-401-in-Chronic-Lymphocytic-Leukemia-and-Follicular-Lymphoma Wed, 31 May 2017 05:30:00 -0700 http://investor.meipharma.com/2017-05-31-MEI-Pharma-Announces-Pre-Specified-Response-Rate-Exceeded-in-Dose-Escalation-Study-of-ME-401-in-Chronic-Lymphocytic-Leukemia-and-Follicular-Lymphoma Helsinn Group and MEI Pharma Announce Upcoming Presentations of Gene Mutation and Clinical Response Data from Phase II Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia http://investor.meipharma.com/2017-05-18-Helsinn-Group-and-MEI-Pharma-Announce-Upcoming-Presentations-of-Gene-Mutation-and-Clinical-Response-Data-from-Phase-II-Study-of-Pracinostat-and-Azacitidine-in-Acute-Myeloid-Leukemia Data to be presented at ASCO and EHA in June; Abstracts now available online Thu, 18 May 2017 06:00:00 -0700 http://investor.meipharma.com/2017-05-18-Helsinn-Group-and-MEI-Pharma-Announce-Upcoming-Presentations-of-Gene-Mutation-and-Clinical-Response-Data-from-Phase-II-Study-of-Pracinostat-and-Azacitidine-in-Acute-Myeloid-Leukemia MEI Pharma Reports Third Quarter Fiscal Year 2017 Results http://investor.meipharma.com/2017-05-04-MEI-Pharma-Reports-Third-Quarter-Fiscal-Year-2017-Results Thu, 04 May 2017 06:00:00 -0700 http://investor.meipharma.com/2017-05-04-MEI-Pharma-Reports-Third-Quarter-Fiscal-Year-2017-Results